# WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease

Study · id `cardio:ct-nct04551456` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04551456](<https://clinicaltrials.gov/study/NCT04551456>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04551456

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT04551456. Randomized; double masking; primary purpose treatment. Start 2020-11-30 (anticipated); primary completion 2021-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT04551456, source copy `cardio:ctgov-nct04551456-2020-09-16`, retrieved 2026-10-26)
- Planned start: 2020-11-30 (anticipated) (ClinicalTrials.gov record NCT04551456, source copy `cardio:ctgov-nct04551456-2020-09-16`, retrieved 2026-10-26)
- Primary completion: 2021-12-30 (anticipated) (ClinicalTrials.gov record NCT04551456, source copy `cardio:ctgov-nct04551456-2020-09-16`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04551456, source copy `cardio:ctgov-nct04551456-2020-09-16`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04551456-2020-09-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
- Acronym: WANICHD
- Condition: Coronary Artery Disease
- Intervention (Biological): Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
- Lead sponsor: Navy General Hospital, Beijing
- Lead sponsor class: OTHER
- Collaborator: Chinese PLA General Hospital
- Collaborator class: OTHER
- Collaborator: Peking University Third Hospital
- Collaborator class: OTHER
- Collaborator: Peking Union Medical College Hospital
- Collaborator class: OTHER
- Collaborator: Xijing Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Navy General Hospital, Beijing (`cardio:org-navy-general-hospital-beijing`)
- Registry lists this organization as a collaborator: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)
- Registry lists this organization as a collaborator: Peking University Third Hospital (`cardio:org-peking-university-third-hospital`)
- Registry lists this organization as a collaborator: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)
- Registry lists this organization as a collaborator: Xijing Hospital (`cardio:org-xijing-hospital`)

## Provenance

Content hash: c3c2b6016bae07562b3237ad0fe147d848b6457bada83c1ebb216da20fd8081c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
